Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is projected to announce its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Editas Medicine to post earnings of ($0.27) per share and revenue of $8.7680 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Editas Medicine Stock Performance

Shares of EDIT opened at $2.11 on Wednesday. The stock has a 50-day moving average of $2.03 and a two-hundred day moving average of $2.61. The stock has a market cap of $205.98 million, a P/E ratio of -0.89 and a beta of 2.15. Editas Medicine has a one year low of $0.91 and a one year high of $4.54.

Analyst Ratings Changes

A number of equities research analysts recently commented on EDIT shares. Chardan Capital raised Editas Medicine from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Editas Medicine currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EDIT. Renaissance Technologies LLC lifted its holdings in Editas Medicine by 138.0% in the fourth quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock valued at $6,232,000 after acquiring an additional 1,762,378 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Editas Medicine by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company’s stock valued at $4,685,000 after purchasing an additional 244,574 shares during the period. State Street Corp boosted its holdings in Editas Medicine by 2.6% during the fourth quarter. State Street Corp now owns 1,974,931 shares of the company’s stock worth $4,049,000 after buying an additional 49,887 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Editas Medicine by 63.3% during the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock valued at $5,497,000 after buying an additional 614,229 shares during the period. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.